Azapiron

Izvor: Wikipedija
Prijeđi na navigaciju Prijeđi na pretragu
Buspiron, prototipski azapironski angziolitik, koji sadrži azaspirodekandion i pirimidinilpiperazin vezan preko butil lanca.

Azapironi su klasa lekova koji se koriste kao anksiolitici i antipsihotici.[1][2][3][4] Oni se isto tako koriste kao zamena za antidepresive poput selektivnih inhibitora preuzimanja serotonina (SSRI).[5][6][7][8][9]

Reference[uredi | uredi kod]

  1. Eison AS (June 1990). „Azapirones: history of development”. Journal of Clinical Psychopharmacology 10 (3 Suppl): 2S–5S. PMID 1973936. 
  2. Cadieux RJ (May 1996). „Azapirones: an alternative to benzodiazepines for anxiety”. American Family Physician 53 (7): 2349–53. PMID 8638511. 
  3. Chessick CA, Allen MH, Thase M, et al. (2006). Chessick, Cheryl A. ur. „Azapirones for generalized anxiety disorder”. Cochrane Database of Systematic Reviews (Online) 3: CD006115. DOI:10.1002/14651858.CD006115. PMID 16856115. 
  4. Feighner JP, Boyer WF (1989). „Serotonin-1A anxiolytics: an overview”. Psychopathology 22 Suppl 1: 21–6. PMID 2567039. 
  5. Van Ameringen M, Mancini C, Wilson C (July 1996). „Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia”. Journal of Affective Disorders 39 (2): 115–21. DOI:10.1016/0165-0327(96)00030-4. PMID 8827420. 
  6. Bouwer C, Stein DJ (April 1997). „Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression”. South African Medical Journal 87 (4 Suppl): 534–7, 540. PMID 9180827. 
  7. Dimitriou EC, Dimitriou CE (December 1998). „Buspirone augmentation of antidepressant therapy”. Journal of Clinical Psychopharmacology 18 (6): 465–9. DOI:10.1097/00004714-199812000-00009. PMID 9864079. 
  8. Appelberg BG, Syvälahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH (June 2001). „Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study”. The Journal of Clinical Psychiatry 62 (6): 448–52. DOI:10.4088/JCP.v62n0608. PMID 11465522. 
  9. Yamada K, Yagi G, Kanba S (April 2003). „Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: a randomized controlled trial”. Psychiatry and Clinical Neurosciences 57 (2): 183–7. DOI:10.1046/j.1440-1819.2003.01099.x. PMID 12667165. [mrtav link]